113 related articles for article (PubMed ID: 11146571)
1. Bone marrow stromal cell distribution of basic fibroblast growth factor in chronic myeloid disorders.
Yoon SY; Tefferi A; Li CY
Haematologica; 2001 Jan; 86(1):52-7. PubMed ID: 11146571
[TBL] [Abstract][Full Text] [Related]
2. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodysplastic syndrome with myelofibrosis and related disorders.
Yoon SY; Li CY; Lloyd RV; Tefferi A
Int J Hematol; 2000 Oct; 72(3):337-42. PubMed ID: 11185990
[TBL] [Abstract][Full Text] [Related]
4. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia.
Keith T; Araki Y; Ohyagi M; Hasegawa M; Yamamoto K; Kurata M; Nakagawa Y; Suzuki K; Kitagawa M
Br J Haematol; 2007 May; 137(3):206-15. PubMed ID: 17408459
[TBL] [Abstract][Full Text] [Related]
5. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
7. von Willebrand factor is the most reliable immunohistochemical marker for megakaryocytes of myelodysplastic syndrome and chronic myeloproliferative disorders.
Chuang SS; Jung YC; Li CY
Am J Clin Pathol; 2000 Apr; 113(4):506-11. PubMed ID: 10761451
[TBL] [Abstract][Full Text] [Related]
8. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders.
Del Cañizo MC; Brufau A; Mota A; Lopez N; Fernandez ME; Vallejo C; Hernandez JM; Garcia JL; San Miguel JF
Haematologica; 1998 Jan; 83(1):3-7. PubMed ID: 9580461
[TBL] [Abstract][Full Text] [Related]
9. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
Tauro S; Hepburn MD; Bowen DT; Pippard MJ
Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
[TBL] [Abstract][Full Text] [Related]
10. [LAT (linker for activation of T cells): a useful marker for megakaryocyte evaluation on bone marrow biopsies].
Ungari M; Pellegrini W; Borlenghi E; Marocolo D; Ubiali A; Agazzi C; Pich A; Franco V; Facchetti F
Pathologica; 2002 Dec; 94(6):325-30. PubMed ID: 12540999
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
12. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
13. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
[TBL] [Abstract][Full Text] [Related]
14. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
15. [The implications of the biological indices examination of bone marrow cells in myelodysplastic syndromes].
Zhang F; Hao Y; Pang W
Zhonghua Xue Ye Xue Za Zhi; 2001 Oct; 22(10):528-32. PubMed ID: 11769678
[TBL] [Abstract][Full Text] [Related]
16. Peripheral T-cell lymphoma presenting as myelofibrosis with the expression of basic fibroblast growth factor.
Kikukawa M; Umahara T; Kikawada M; Kanaya K; Sakurai H; Shin K; Mori M; Iwamoto T
Geriatr Gerontol Int; 2009 Dec; 9(4):395-8. PubMed ID: 20002760
[TBL] [Abstract][Full Text] [Related]
17. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
[TBL] [Abstract][Full Text] [Related]
18. Effect of forced expression of basic fibroblast growth factor in human bone marrow-derived mesenchymal stromal cells.
Go MJ; Takenaka C; Ohgushi H
J Biochem; 2007 Dec; 142(6):741-8. PubMed ID: 17956905
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
[TBL] [Abstract][Full Text] [Related]
20. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity.
Schmitt-Graeff A; Thiele J; Zuk I; Kvasnicka HM
Haematologica; 2002 Apr; 87(4):392-9. PubMed ID: 11940483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
